AKAP17A and acute lymphoblastic leukemia: Both therapies target the B-lymphocyte antigen CD19 and are approved: tisagenlecleucel for pediatric acute lymphoblastic leukemia (ALL) and adult diffuse large B-cell lymphoma subtypes (DLBCL), and axicabtagene ciloleucel for DLBCL (1, 2).